期刊
THORACIC CANCER
卷 12, 期 9, 页码 1373-1381出版社
WILEY
DOI: 10.1111/1759-7714.13913
关键词
anti‐ PD‐ L1 antibody; chemotherapy; esophageal squamous cell carcinoma; liposomal irinotecan
资金
- Jiangsu Hengrui Medicine Co. Ltd.
The study demonstrates that SHR-1316 plus liposomal irinotecan and 5-fluorouracil shows promising efficacy and manageable safety profile as a first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). The median progression-free survival (PFS) was 8.5 months, with an objective response rate (ORR) of 52.2% and disease control rate (DCR) of 73.9%.
Background This multicentre, open-label study evaluated the efficacy and safety of antiprogrammed death ligand 1 antibody SHR-1316 plus liposomal irinotecan and 5-fluorouracil as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC). Methods Eligible patients received SHR-1316 (10 mg/kg), liposomal irinotecan (60 mg/m(2) for the first cycle, 80 mg/m(2) thereafter), and 5-fluorouracil (2400 mg/m(2)) every 14 days until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Results We enrolled 23 patients between 11 March 2019 and 31 May 2019. The median follow-up duration was 15.2 months (95% CI 14.2-16.2). The median PFS was 8.5 months (95% CI 1.2-15.8), and ORR and DCR were 52.2% (95% CI 30.1-74.3) and 73.9% (95% CI 54.5-93.3), respectively. The median OS was 11.6 months (95% CI 6.7-16.6). The most common treatment-related grade 3-4 adverse events (AEs) were neutropenia (17.4%), nausea (13.0%), and anorexia (13.0%). Treatment-related serious AEs occurred in two patients. No treatment-related deaths occurred. Conclusions SHR-1316 plus liposomal irinotecan and 5-fluorouracil has a promising efficacy and manageable safety profile, and could be a new first-line treatment approach for patients with unresectable locally advanced or distant metastatic ESCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据